PubAg

Main content area

Immunogenicity and reactogenicity of co-administered tetanus–diphtheria–acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration

Author:
Weston, Wayde M., Friedland, Leonard R., Wu, Xiangfeng, Howe, Barbara
Source:
Vaccine 2011 v.29 no.5 pp. 1017-1022
ISSN:
0264-410X
Subject:
adolescents, antibodies, antigens, immune response, serotypes, tetanus, vaccines, United States
Abstract:
In the United States, co-administration of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine and tetravalent meningococcal conjugate vaccine (MCV4) is recommended in adolescents. In this clinical study, 1341 adolescents received Tdap (Boostrix® GlaxoSmithKline) and MCV4 (Menactra®, Sanofi-Pasteur) simultaneously or sequentially one month apart. Co-administration of Tdap+MCV4 was well tolerated and immunogenic, resulting in high levels of antibodies against diphtheria, tetanus, pertussis and meningococcal serogroup A,C,W-135 and Y antigens. The data provide support for current recommendations for co-administration of Tdap and MCV4 vaccines at the same office visit.
Agid:
1109951